Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Who We Are

Viracta is clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.

Recent News

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership - Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

Events

February 28 - March 1, 2018

David Slack will be presenting at Biocom's Global Life Science Partnering Conference in San Diego Read More

April 20, 2017

Ivor Royston will speak at The 8th China-US Business Leaders Conference in New York City Agenda | Ascentage Forum

April 7, 2017

Viracta selected to present at BioCentury’s Future Leaders in the Biotech Industry Conference Read More

Recent News

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat - San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership - Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

Events

February 28 - March 1, 2018

David Slack will be presenting at Biocom's Global Life Science Partnering Conference in San Diego Read More

April 20, 2017

Ivor Royston will speak at The 8th China-US Business Leaders Conference in New York City Agenda | Ascentage Forum

April 7, 2017

Viracta selected to present at BioCentury’s Future Leaders in the Biotech Industry Conference Read More